Very intereating?
why reduce the dosage? I assume it’s well tolerated given it’s an NK treatment.
why add more cancer indications?
this could potentially be attributed to early efficacy signals and they want to examine the therapy on broader cancer indications
Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-19
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $9.724K | 2.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3932543 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18587873 | 22 |
View Market Depth
| Last trade - 11.20am 27/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |